Objective: To investigate predictors of trial start-up times, high attrition, and poor protocol adherence in amyotrophic lateral sclerosis (ALS) trials.Methods: Retrospective analysis of start-up times, retention, and protocol adherence was performed on 5 clinical studies conducted by the Northeast ALS Consortium and 50 ALS clinical trials identified by PubMed search. Predictors of start-up times were estimated by accelerated failure time models with random effects. Predictors of retention and protocol deviations were estimated by mixed-model logistic regression.Results: Median times for contract execution and institutional review board (IRB) approval were 105 days and 125 days, respectively. Contract execution was faster at sites with more ongoing trials (p 5 0.005), and more full-time (p 5 0.006) and experienced (p , 0.001) coordinators. IRB approval was faster at sites with more ongoing trials (p 5 0.010) and larger ALS clinics (p 5 0.038). Site activation after IRB approval was faster at sites with more full-time (p 5 0.038) and experienced (p , 0.001) coordinators. Twenty-two percent of surviving participants withdrew before completing the trial. Better participant functional score at baseline was an independent predictor of trial completion (odds ratio 1.29, p 5 0.002) and fewer protocol deviations (odds ratio 0.86, p 5 0.030).Conclusion: Delays in IRB review contribute the most to prolonged trial start-up times, and these timelines are faster in sites with more experienced staff. Strategies to improve protocol adherence and participants' retention may include enrolling people at early disease stages. The translation of basic research to clinical practice depends on the conduct of well-designed and efficient clinical trials. Delays in study start-up, high participant attrition, and poor adherence to the study protocol reduce trial validity and inflate the timelines and costs of drug development. In published clinical trials, enrollment and retention data are routinely reported; however, factors affecting study start-up times, retention, and adherence to the protocol are rarely mentioned.
1,2Conducting efficient clinical trials involves completing study start-up processes in a timely manner. This includes execution of the site contracts, obtaining institutional review board (IRB) approvals, and completing protocol, pharmacy, and outcomes trainings. Delays in the study start-up process can extend trial duration and costs, threaten trial feasibility, and delay answering important clinical questions.The internal validity of a clinical trial depends largely on good conduct including retention and maintaining good protocol adherence (i.e., complying with the study protocol). In addition, high attrition requires larger sample sizes to maintain statistical power and subsequently inflates trial duration and costs. 3,4 Amyotrophic lateral sclerosis (ALS) is a rare neurologic disorder that has many potential therapies currently in development.5 With a small patient population and limited funds, it is critical